VB Spine Announces Intent to Acquire Exclusive Rights to Augmedics’ Spine Platform




VB Spine Announces Intent to Acquire Exclusive Rights to Augmedics’ Spine Platform

Transaction will expand VB Spine’s enhanced visualization portfolio to include augmented reality navigation with the Augmedics xvision Spine System®

NEW YORK & CHICAGO–(BUSINESS WIRE)–VB Spine LLC (“VB Spine”), the largest privately held spine company, today announced it has entered into a definitive agreement to acquire exclusive rights to the xvision Spine System® (xvision) from Augmedics, adding augmented reality (AR) navigation to VB Spine’s growing enhanced visualization portfolio. Augmedics is the first company to offer an FDA-cleared AR navigation platform in spine surgery, positioning VB Spine to become a world leader in AR-enabled spine solutions. The transaction is subject to approval and customary closing conditions and is expected to close in the coming weeks.

The xvision Spine System is designed to combine the benefits of navigation with the ease and utility of open surgery: visualization while looking directly at the patient, accuracy and precision, workflow efficiency, and radiation reduction. With nearly 13,000 patients treated with xvision, the transaction brings together two complementary portfolios focused on redefining spine care.

This transaction marks a foundational element in a broader enhanced visualization technology strategy for the company, building on the recent acquisition of the SpineHawk™ intraoperative spinal visualization platform from Robotron Surgical Technologies.

“We have long admired the xvision technology and potential of the platform,” said Marc Viscogliosi, co-CEO of VB Spine. “We believe with our implant integration and scale, we have the ability to harness the true potential of AR navigation. Combined with the SpineHawk platform, this will expand our existing spine solutions and supports our long-term roadmap to redefine spine care with differentiated technologies.”

“We are proud of the clinical impact xvision has made in spine surgery and VB Spine’s commitment to our world-class portfolio,” said Paul Ziegler, President and CEO of Augmedics. “This agreement will strengthen our competitive advantage as an augmented reality innovation engine as we turn our focus to expanding our reach into adjacent surgical indications.”

Subject to approval and closing, VB Spine and Augmedics intend to work together to support an orderly transition for customers.

Regulatory and Availability

The xvision Spine System® with xvision Spine System Software is FDA-cleared in the US. It is intended as an aid for precisely locating anatomical structures in either open, minimally invasive, or percutaneous spine procedures.

Forward-Looking Statements

Certain statements in this release are forward-looking and are based on current expectations, forecasts, and assumptions. Actual results may differ materially due to regulatory, commercial, and operational risks. VB Spine disclaims any obligation to update forward-looking statements except as required by law.

About VB Spine

VB Spine LLC is the largest privately held spine company and among the largest family-owned medical technology companies in the world. With a comprehensive portfolio and a large and growing global distribution network, VB Spine delivers specialized solutions that address critical needs in spine surgery and enhance patient outcomes. Focused on people, partnerships, and operational excellence, VB Spine ensures healthcare professionals have access to the tools and resources needed to provide the highest standard of care. VB Spine is owned and led by the Viscogliosi Brothers. For more information on VB Spine, please visit www.vbspineco.com.

About Augmedics

Augmedics pioneers cutting-edge augmented reality technologies to improve surgical outcomes. Its revolutionary xvision Spine System® enables surgeons to visualize a patient’s anatomy as though they have “x-ray vision,” allowing for precise navigation of instruments and implants during procedures. The first-of-its-kind, FDA-cleared xvision has been used in nearly 13,000 spinal procedures, redefining surgical visualization for spine surgery. Augmedics remains committed to transforming surgery through breakthrough innovation and advancing AR navigation into adjacent specialties. To learn more, visit augmedics.com.

Contacts

For media inquiries only:
spinecommunications@vbspineco.com and info@augmedics.com

Europe Oncology Genomics Tracker Captures Oncologist Perspectives Across Major European Markets – Data Report by DeciBio Consulting LLC




Europe Oncology Genomics Tracker Captures Oncologist Perspectives Across Major European Markets – Data Report by DeciBio Consulting LLC

LOS ANGELES–(BUSINESS WIRE)–#MRD–A new survey-based Genomics Tracker focused on the EU-5 (France, Germany, Italy, Spain, and the United Kingdom) by DeciBio Consulting LLC provides updated insight into how genomics technologies are being evaluated, adopted, and used across Europe’s solid tumor oncology markets. The study is based on responses from 100+ medical oncologists and offers a cross-market view of current priorities, barriers, and areas of momentum.

The Europe Oncology Genomics Tracker characterizes the current clinical use of genomic testing across a patient’s treatment journey (e.g., genomic profiling, MRD / recurrence monitoring, treatment response monitoring) and tracks how use changes over time. Oncology respondents were asked about their use of genomic testing in routine clinical practice within the past three months, as well as their familiarity with various vendors in the ecosystem.

The survey was distributed randomly to oncologists practicing in the UK, France, Germany, Italy, or Spain. Respondents were selected to complete the survey if they were actively practicing medical oncologists or hematologist-oncologists and had seen at least 25 patients in the past three months. Respondents were not excluded from the survey if they were not currently using, or had not previously used, genomics for biomarker testing.

DeciBio Partner and leading author of the tracker, Andrew Aijian, notes the value of integrating the EU tracker into a broader suite of genomics trackers, “Adoption of precision medicine is growing steadily across Europe, though each market presents unique drivers and moderators. The country-specific healthcare frameworks and infrastructure in Europe require different strategies for precision oncology than what we see in the U.S. Having visibility into genomics testing practices in these regions is critical for any precision oncology stakeholder to identify opportunities and risks, and develop locally-optimized strategies.”

Based on recent clinician survey data, the tracker quantifies real-world adoption of testing for treatment selection, detailing tissue versus liquid biopsy use, panel size mix, provider awareness and perception, and the competitive dynamics shaping ordering behavior. It extends beyond profiling to capture emerging use of ctDNA for MRD, recurrence, and treatment response monitoring, highlighting utilization by care setting, confidence in clinical utility, vendor share shifts, pain points, and sales and marketing visibility. Together, these insights enable biopharma, diagnostics, and investors to benchmark performance, identify inflection points in adoption, and prioritize commercial and evidence-generation strategies grounded in current EU clinical practice.

Learn more about DeciBio’s Europe Oncology Genomics Tracker: https://www.decibio.com/product/europe-oncology-genomics-tracker

While this tracker is inaugural for the European oncology market, it complements DeciBio’s U.S. Oncology Genomics Tracker. This tool is also distributed on a quarterly basis and similarly aims to characterize current clinical use of genomic testing across genomic profiling, MRD / recurrence monitoring, and treatment response monitoring, as well as track changes over time in the United States.

Learn more about DeciBio’s U.S Oncology Genomics Tracker: https://www.decibio.com/product/u-s-oncology-genomics-tracker

About DeciBio:

DeciBio Consulting (www.decibio.com) is the leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating innovation in precision medicine.

Headquartered in Los Angeles, California, DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.

Contacts

Hannah Glazier

glazier@decibio.com

Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research




Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research

CRO expands oncology, adds functional service provider capabilities, strengthens global reach, and accelerates technology to enhance customer value

RESEARCH TRIANGLE PARK, N.C. & NOTTINGHAM, England–(BUSINESS WIRE)–#CROleader—Worldwide Clinical Trials (“Worldwide” or the “Company”), a global contract research organization (CRO), has completed its acquisition of Catalyst Clinical Research, LCC (“Catalyst”) – a specialized oncology CRO and scalable functional service provider (FSP). This strategic transaction creates a combined organization with highly complementary strengths in oncology, biometrics, and FSP capabilities, substantially enhancing Worldwide’s offerings to biopharma customers globally and expanding its employee base to approximately 4,400 across more than 70 countries.

The addition of Catalyst’s deep expertise in early phase oncology, along with its robust FSP model, significantly augments Worldwide’s scientific depth, operational agility, and therapeutic strengths across neuroscience, oncology, rare disease, and internal medicine. Customers now have access to an expanded suite of services, innovative technology platforms, and a broader global site network – supporting efficient, transparent, and flexible development across the clinical trial lifecycle.

“The acquisition of Catalyst strengthens Worldwide’s capabilities in a very deliberate way, building a stronger, more capable CRO partner for our customers,” said Alistair Macdonald, Chief Executive Officer of Worldwide. “It expands our reach into earlier phase oncology, adds targeted FSP and biometrics capabilities, and accelerates our technology platforms, allowing us to better support customers across the full development lifecycle with greater speed, flexibility, and transparency.”

“The completion of the Catalyst acquisition deepens Worldwide’s oncology offering and global reach,” said Matt Jennings, Executive Chairman of Worldwide and Senior Operating Partner of Kohlberg, the majority owner of the Company. “Catalyst’s expertise, technology, and strong biotech relationships are a natural fit for Worldwide and reinforce our strategy to build a differentiated, technology-enabled CRO.”

“Joining the Worldwide team is an exciting next chapter for Catalyst,” said Nik Morton, former President and CEO of Catalyst, who joins Worldwide as EVP, Chief Strategy & Transformation Officer. “We are energized by the cultural alignment between our teams and share a deep commitment to scientific excellence, operational integrity, and a people-first approach. Together, we are well positioned to deliver even greater value to customers worldwide.”

In addition to Morton, Catalyst’s Chairman of the Board, Nick Dyer, joins Worldwide’s Board of Directors. An integration team has been established, with a comprehensive plan underway to ensure a smooth and effective transition for employees, customers, and partners. The Company will leverage its best strengths and practices to unlock new growth and innovation opportunities for customers.

Worldwide acquired Catalyst for an undisclosed amount.

Worldwide is a portfolio company of Kohlberg. Based in Mount Kisco, N.Y., Kohlberg invests in healthcare and services companies. Prior to the deal closing, Catalyst was a portfolio company of QHP Capital, L.P. (“QHP Capital”). QHP Capital is based in Research Triangle Park, N.C., and invests in life sciences and pharma services companies.

BofA Securities served as exclusive advisor and Smith Anderson served as legal counsel to Catalyst. Greenberg Traurig, LLP served as legal counsel to Worldwide.

About Worldwide Clinical Trials

Worldwide Clinical Trials (Worldwide) is a global CRO serving development-driven biopharmaceutical companies, with more than 4,400 professionals operating across more than 70 countries. The company delivers therapeutically dedicated expertise in neuroscience, oncology, rare disease, and internal medicine, with comprehensive support across every development phase – from early-stage and first-in-human studies through Phase III registration trials.

The company’s flexible service model – spanning full-service trial management to functional service partnerships through Worldwide Flex – is powered by a people-first, partnership-driven outsourcing approach that strengthens collaboration, enhances data transparency, and supports more informed decision making. This provides sponsors with tailored, adaptable solutions that keep pace with the evolving demands of clinical research. Learn more at www.worldwide.com.

Contacts

Media Contact:
Jill Shahravar

Jill.Shahravar@worldwide.com
919-389-9253

Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials




Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

LONDON & NEW YORK–(BUSINESS WIRE)–$CMPS #Biotech–Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ongoing Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The company will be disclosing new clinical data from Part A and Part B from COMP005 and Part A from COMP006. The results are scheduled for release on February 17th at 6:30 am ET, followed by a webinar hosted by Compass management at 8:00 am ET.

Live Webcast

Compass management will host a live audio webcast on February 17th at 8:00 am ET. The webcast will be accessible at this link: https://lifescievents.com/event/hz02j0rpw/

A replay of the webcast will be accessible for 30 days following the event.

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

Compass is headquartered in London, UK, with offices in New York in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.

Contacts

Enquiries

Media: Dana Sultan-Rothman, media@compasspathways.com
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

New ECCO data show subcutaneous (SC) infliximab (Remsima™  SC) effectively recaptures and maintains disease control after drug holiday




New ECCO data show subcutaneous (SC) infliximab (Remsima™  SC) effectively recaptures and maintains disease control after drug holiday

• A new post-hoc analysis from the LIBERTY studies, presented at ECCO 2026, demonstrated that initiating subcutaneous (SC) infliximab (Remsima™ SC) after a treatment interruption following intravenous (IV) infliximab induction helps patients with Crohn’s disease (CD) and ulcerative colitis (UC) recapture and maintain disease control¹
• The results demonstrated that SC infliximab provides an effective and safe option to regain clinical control after a planned or unplanned treatment interruption
• More than a total of 30 accepted abstracts including one oral and one digital oral presentation and eight posters, reinforce Celltrion’s commitment to inflammatory bowel disease (IBD) research aimed at enhancing patient outcomes

INCHEON, South Korea–(BUSINESS WIRE)–Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients with sustained efficacy, safety, and persistence through to Week 102.¹ The data will be presented as a poster presentation at the 21^st Congress of the European Crohn’s and Colitis Organisation (ECCO), to be held from February 18-21 in Stockholm, Sweden.

“As immunogenicity is the most significant concern when restarting treatment with infliximab after an interruption, these results suggest that treatment persistence was maintained even in patients with immunogenicity,” said Dr. Marla Dubinsky, Professor of Pediatrics and Director of the IBD Center at the Icahn School of Medicine at Mount Sinai. “It’s reassuring to see that not only can we effectively recapture disease control with a convenient subcutaneous option, but that this response was seen early and was shown to be maintained through Week 102 in a post-hoc analysis from the pivotal LIBERTY studies. This is a significant finding for patients, as it offers a potentially reliable strategy for providers and transformative opportunity for patients to manage their IBD journey even when treatment is interrupted.”

“In clinical practice, patients may experience treatment interruption for clinical and non-clinical reasons, and initiation of treatment demands careful consideration of the risks,” said Professor Stefan Schreiber, University Hospital Schleswig-Holstein, Department of Medicine I, Kiel, Germany. “This data provides evidence that subcutaneous infliximab can effectively and safely recapture disease control, offering a viable treatment option for both clinicians and patients.”

The analysis evaluated the efficacy and safety of starting SC infliximab 240mg in patients, randomised to the placebo maintenance arm in the Phase 3 LIBERTY studies, who had previously completed intravenous (IV) infliximab induction and subsequently experienced a drug holiday of 16 weeks or more before starting SC infliximab due to disease progression.

Among 51 CD and 77 UC patients who initiated treatment with SC infliximab, clinical response was observed early by 8±2 weeks and was maintained through the study. At the end of the treatment, 61.1% in CD and 65.2% in UC patients achieved faecal calprotectin remission, and 64.0% in CD and 68.8% in UC patients achieved endoscopic response/ improvement. Persistence in treatment end was 72.3% of CD patients and 61.9% of UC patients. Serum infliximab levels increased after initiating SC infliximab and remained stable through Week 102, with no new safety concerns observed.

The results demonstrated that initiation of treatment with SC infliximab 240 mg was effective to recapture and maintain disease control for Crohn’s disease (CD) and ulcerative colitis (UC) patients, suggesting SC infliximab provides an effective and safe option to regain clinical control after a planned or unplanned treatment interruption.

Additionally, Celltrion will host a satellite symposium titled, “Enhancing Patient Management with Subcutaneous Infliximab: Practical Insights & Discussion.” on Friday, February 20 from 12:45 to 13:25, in Room A12 at Stockholmsmässan. Chaired by Professor Jean-Frédéric Colombel, the symposium will feature presentations from Professor Anthony Buisson and Professor Axel Dignass.

“The comprehensive data from the studies reinforces the growing body of evidence supporting subcutaneous infliximab as a critical treatment option for the gastroenterology community,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “The data presented at ECCO 2026 further demonstrate our leadership and long-standing commitment to raising standards of care in gastroenterology and to improving the lives of people with Inflammatory Bowel Disease.”

Notes to Editors:

About the subcutaneous (SC) formulation of CT-P13

CT-P13 SC is the world’s first subcutaneous formulation of infliximab. A 120mg fixed dose of CT-P13 SC has been approved for use in 60 countries including the US, UK, EU, Canada, Brazil, Australia and Taiwan, in adults regardless of body weight. The SC formulation of infliximab has the potential to enhance treatment options by providing high consistency in drug exposure and a convenient method of administration.^2,3 In July 2024, CT-P13 SC received final approval from the European Commission for an additional dosing regimen and dose escalation, which allows 3-intraveneous (IV) induction dosing regimen and dose escalation of subcutaneous maintenance dose from CT-P13 SC 120 mg Q2W to 240 mg Q2W for patients with loss of response.⁴ Long term data from two-year extension of the LIBERTY studies (LIBERTY-CD and LIBERTY-UC) have demonstrated sustained efficacy and safety of CT-P13 SC, with clinical remission, response, and corticosteroid-free remission generally maintained through Week 102.⁵

About Celltrion

Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, haematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media – LinkedIn, Instagram, X, and Facebook.

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, “anticipates”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries’ management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.

Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

References

Contacts

For further information please contact:
Donna Gandhi

dgandhi@hanovercomms.com
+44 (0) 7827 053 502

Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease




Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease

– MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years –

– Up to 30% of people with membranous nephropathy progress to kidney failure over 10 years despite current treatment approaches; achieving complete remission can help delay or prevent this –

– Gazyva could become the first approved treatment for primary membranous nephropathy, having already achieved positive results in lupus nephritis, systemic lupus erythematosus and idiopathic nephrotic syndrome –

– Gazyva is a glycoengineered, anti-CD20 monoclonal antibody designed to achieve deep tissue B cell depletion –

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistically significant and clinically meaningful results with Gazyva^® (obinutuzumab). Results show that significantly more people achieved complete remission at two years (104 weeks) with Gazyva versus tacrolimus. Safety was in line with the well-characterized profile of Gazyva and no new safety signals were identified.

“These results demonstrate that Gazyva may help more people with primary membranous nephropathy achieve complete remission, maintain kidney function for longer and delay or potentially prevent the onset of life-threatening complications,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “If approved, Gazyva would be the first therapy specifically indicated for people with primary membranous nephropathy, where there are limited treatment options.”

Analysis of key secondary endpoints showed statistically significant and clinically meaningful benefits with Gazyva versus tacrolimus in overall remission (complete or partial remission) at week 104 and complete remission at week 76.

Data will be presented at an upcoming medical meeting and shared with health authorities including the U.S. Food and Drug Administration and the European Medicines Agency.

Primary membranous nephropathy is a chronic autoimmune condition that causes potentially irreversible kidney damage and reduced kidney function, and it is estimated that it affects over 96,000 people in the U.S. Up to 30% of people with primary membranous nephropathy will develop kidney failure over 10 years, which requires invasive intervention like dialysis or transplant and has a significant impact on patients and their families, as well as carrying substantial cost to health systems. Gazyva has the potential to address this by targeting an underlying cause of the condition, which may help maintain kidney function for longer and prevent the onset of life-threatening complications.

MAJESTY is the fourth positive Phase III study of Gazyva in immune-mediated diseases, following REGENCY in lupus nephritis, ALLEGORY in systemic lupus erythematosus and INShore in idiopathic nephrotic syndrome. This growing body of evidence supports Gazyva’s potential in addressing disease activity across a spectrum of immune-mediated diseases.

Gazyva is approved in the U.S. and European Union for the treatment of adults with active lupus nephritis based on data from the REGENCY and NOBILITY studies and is being investigated in a global Phase II study of children and adolescents with lupus nephritis. Beyond Gazyva, we have a broad pipeline as part of our ambition to be leaders in immunology, in particular in immune-mediated and kidney-related diseases.

About Gazyva

Gazyva^® (obinutuzumab) is a humanized monoclonal antibody designed with a Type II anti-CD20 region, for direct B cell death and a glycoengineered Fc region, for higher binding affinity and increased antibody-dependent cellular cytotoxicity (ADCC). CD20 is a protein found on certain types of B cells. Gazyva is approved for adults with lupus nephritis in the US and EU. Gazyva is also approved in 100 countries for various types of hematological cancers.

About the MAJESTY Study

MAJESTY [NCT04629248] is a Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of Gazyva^® (obinutuzumab) in people with primary membranous nephropathy. The study enrolled 142 people who were randomized 1:1 to receive Gazyva or tacrolimus. The primary endpoint is the percentage of people who achieve complete remission at two years (week 104).

About Primary Membranous Nephropathy

Primary membranous nephropathy is a chronic autoimmune condition where the body’s immune system attacks the filtering units of the kidney, the glomeruli, causing protein to leak into the urine and potentially a gradual decline in kidney function. Over time, the damage to the kidneys can become irreversible, increasing the risk of life-threatening complications, such as kidney failure, idiopathic nephrotic syndrome, blood clots and cardiovascular disease. Achieving complete remission is critical to help maintain kidney function and delay or prevent the onset of serious and potentially fatal complications.

GAZYVA Indications

GAZYVA^® (obinutuzumab) is a prescription medicine used:

• With the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment
• With the chemotherapy drug, bendamustine, followed by GAZYVA alone for follicular lymphoma (FL) in adults who did not respond to a rituximab-containing regimen, or whose FL returned after such treatment
• With chemotherapy, followed by GAZYVA alone in those who responded, to treat stage II bulky, III, or IV FL in adults who have not had previous FL treatment
• For the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy

Important Safety Information

The most important safety information patients should know about GAZYVA

Patients must tell their doctor right away about any side effect they experience. GAZYVA can cause side effects that can become serious or life-threatening, including:

• Hepatitis B Virus (HBV): Hepatitis B can cause liver failure and death. If the patient has a history of hepatitis B infection, GAZYVA could cause it to return. Patients should not receive GAZYVA if they have active hepatitis B liver disease. The patient’s doctor or healthcare team will need to screen them for hepatitis B before, and monitor the patient for hepatitis during and after, their treatment with GAZYVA. Sometimes this will require treatment for hepatitis B. Symptoms of hepatitis include: worsening of fatigue and yellow discoloration of skin or eyes.
• Progressive Multifocal Leukoencephalopathy (PML): PML is a rare and serious brain infection caused by a virus. PML can be fatal. The patient’s weakened immune system could put them at risk. The patient’s doctor will watch for symptoms. Symptoms of PML include: confusion, difficulty talking or walking, dizziness or loss of balance, and vision problems.

Who should not receive GAZYVA:

Patients should NOT receive GAZYVA if they have had an allergic reaction (e.g., anaphylaxis or serum sickness) to GAZYVA. Patients must tell their healthcare provider if they have had an allergic reaction to obinutuzumab or any other ingredients in GAZYVA in the past.

Additional possible serious side effects of GAZYVA:

Patients must tell their doctor right away about any side effect they experience. GAZYVA can cause side effects that may become severe or life-threatening, including:

• Infusion-Related Reactions: These side effects may occur during or within 24 hours of any GAZYVA infusion. Some infusion-related reactions can be serious, including, but not limited to, severe allergic reactions (anaphylaxis), acute life-threatening breathing problems, or other life-threatening infusion-related reactions. If the patient has a reaction, the infusion is either slowed or stopped until their symptoms are resolved. Most patients are able to complete infusions and receive medication again. However, if the infusion-related reaction is life-threatening, the infusion of GAZYVA will be permanently stopped. The patient’s healthcare team will take steps to help lessen any side effects the patient may have to the infusion process. The patient may be given medicines to take before each GAZYVA treatment. Symptoms of infusion-related reactions may include: fast heartbeat, tiredness, dizziness, headache, redness of the face, nausea, chills, fever, vomiting, diarrhea, rash, high blood pressure, low blood pressure, difficulty breathing, and chest discomfort.
• Hypersensitivity Reactions Including Serum Sickness: Some patients receiving GAZYVA may have severe or life-threatening allergic reactions. This reaction may be severe, may happen during or after an infusion, and may affect many areas of the body. If an allergic reaction occurs, the patient’s doctor will stop the infusion and permanently discontinue GAZYVA
• Tumor Lysis Syndrome (TLS): Tumor lysis syndrome, including fatal cases, has been reported in patients receiving GAZYVA. GAZYVA works to break down cancer cells quickly. As cancer cells break apart, their contents are released into the blood. These contents may cause damage to organs and the heart and may lead to kidney failure requiring the need for dialysis treatment. The patient’s doctor may prescribe medication to help prevent TLS. The patient’s doctor will also conduct regular blood tests to check for TLS. Symptoms of TLS may include nausea, vomiting, diarrhea, and tiredness. TLS is not identified as a risk in LN.
• Serious, Including Fatal, Infections: While the patient is taking GAZYVA, they may develop infections. Some of these infections may be fatal and severe, so the patient should be sure to talk to their doctor if they think they have an infection. Patients administered GAZYVA in combination with chemotherapy, followed by GAZYVA alone are at a high risk of infections during and after treatment. Patients with a history of recurring or chronic infections may be at an increased risk of infection. Patients taking GAZYVA plus standard therapy may be at higher risk for fatal or severe infections compared to patients taking standard therapy plus placebo. Patients with an active infection should not be treated with GAZYVA. Patients taking GAZYVA plus bendamustine may be at higher risk for fatal or severe infections compared to patients taking GAZYVA plus CHOP or CVP. If the patient develops a serious infection, your doctor will immediately discontinue GAZYVA and begin treatment for the infection.
• Low White Blood Cell Count: When the patient has an abnormally low count of infection-fighting white blood cells, it is called neutropenia. While the patient is taking GAZYVA, their doctor will do blood work to check their white blood cell count. Severe and life-threatening neutropenia can develop during or after treatment with GAZYVA. Some cases of neutropenia can last for more than one month. If the patient’s white blood cell count is low, their doctor may prescribe medication to help prevent infections.
• Low Platelet Count: Platelets help stop bleeding or blood loss. GAZYVA may reduce the number of platelets the patient has in their blood; having low platelet count is called thrombocytopenia. This may affect the clotting process. While the patient is taking GAZYVA, their doctor will do blood work to check their platelet count. Severe and life-threatening thrombocytopenia can develop during treatment with GAZYVA. Fatal bleeding events have occurred in patients treated with GAZYVA. If the patient’s platelet count gets too low, their treatment may be delayed or reduced.
• Disseminated Intravascular Coagulation (DIC): Fatal and severe DIC has been reported in people receiving GAZYVA. DIC is a rare and serious abnormal blood clotting condition that should be monitored and managed by the patient’s doctor as it can lead to uncontrollable bleeding.

The most common side effects of GAZYVA in CLL were infusion-related reactions and low white blood cell counts.

The most common side effects seen with GAZYVA in a study that included relapsed or refractory NHL, including FL patients, were infusion-related reactions, fatigue, low white blood cell counts, cough, upper respiratory tract infection, and joint or muscle pain.

The most common side effects seen with GAZYVA in a study that included previously untreated FL patients were infusion-related reactions, low white blood cell count, upper respiratory tract infections, cough, constipation and diarrhea.

The most common side effects of GAZYVA in LN were upper respiratory tract infection, COVID-19, urinary tract infection, bronchitis, pneumonia, infusion-related reactions, and neutropenia.

Before receiving GAZYVA, patients should talk to their doctor about:

• Immunizations: Before receiving GAZYVA therapy, the patient should tell their healthcare provider if they have recently received or are scheduled to receive a vaccine. Patients who are treated with GAZYVA should not receive live vaccines.
• Pregnancy: The patient should tell their doctor if they are pregnant, think that they might be pregnant, plan to become pregnant, or are breastfeeding. GAZYVA may harm their unborn baby. The patient should speak to their doctor about using GAZYVA while they are pregnant. The patient should talk to their doctor or their child’s doctor about the safety and timing of live virus vaccinations to their infant if they received GAZYVA during pregnancy. Women of childbearing potential should use effective contraception while taking GAZYVA and for 6 months after your GAZYVA treatment.
• Breastfeeding: Because of the potential risk of serious side reactions in breastfed children, patients should not breastfeed while taking GAZYVA and for 6 months after your last dose.

Patients should tell their doctor about any side effects.

These are not all of the possible side effects of GAZYVA. For more information, patients should ask their doctor or pharmacist.

GAZYVA is available by prescription only.

Report side effects to the FDA at (800) FDA-1088, or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555.

Please visit https://www.GAZYVA.com for the GAZYVA full Prescribing Information, including BOXED WARNINGS, for additional Important Safety Information.

About Genentech in Immunology

Genentech is committed to harnessing pioneering science and innovation to address critical unmet needs for patients with immune-mediated inflammatory diseases. Our pipeline includes over a dozen clinical programs in immunology aiming to transform care for people living with lupus, MASH, ulcerative colitis, Crohn’s disease, immunoglobulin A nephropathy, idiopathic nephrotic syndrome, atopic dermatitis, and rheumatoid arthritis. We are investing end-to-end in immunology from discovery to R&D to commercialization across a variety of modalities including monoclonal antibodies, bispecifics, and CAR-T cell therapies to help solve some of the most difficult challenges in immunology today.

About Genentech

Founded nearly 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Contacts

Media Contact:

Kendall Tich

(650) 467-6800

Advocacy Contact:

Meg Harrison

(617) 694-7060

Investor Contacts:

Loren Kalm

(650) 225-3217

Bruno Eschli

+41 61 687 5284

Galderma Announces Appointment of New Chief Financial Officer




Galderma Announces Appointment of New Chief Financial Officer

Ad hoc announcement pursuant to Art. 53 LR

ZUG, Switzerland–(BUSINESS WIRE)–Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026.

Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization.

Luigi La Corte brings more than 30 years of international financial leadership experience across healthcare and consumer businesses. Most recently, he served as CFO of the global pharmaceutical company Recordati S.p.A from 2019 – 2025, where he was responsible for Group Finance, Investor Relations, Sustainability and Information Systems. He was appointed to Recordati’s Board of Directors in 2022, a position he continues to hold.

Previously, Luigi La Corte held a range of senior finance leadership roles within the pharmaceutical sector, including positions at GlaxoSmithKline, AstraZeneca and Alliance Unichem, and served as CFO at Pladis Food Group. Earlier in his career he also worked for Bain & Company, PepsiCo and Procter & Gamble. An Italian national, he holds a Master in Economics from Luiss University and is a Fellow of the Chartered Institute of Management Accountants.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

Forward-looking statements

Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “plans”, “targets”, “aims”, ” believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “continues”, “should” and similar expressions. These forward-looking statements reflect, at the time, Galderma’s beliefs, intentions and current targets/ aims concerning, among other things, Galderma’s results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management’s current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.

Contacts

For further information:

Media

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com
+41 76 210 60 62

Investors

Emil Ivanov

Head of Strategy, Investor Relations and ESG

emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com
+41 21 642 76 43

Enpro Increases Quarterly Dividend




Enpro Increases Quarterly Dividend

CHARLOTTE, N.C.–(BUSINESS WIRE)–Enpro Inc. (NYSE: NPO) today declared a quarterly dividend of $0.32 per share, a 3.2% increase from the previous $0.31 per share quarterly dividend. Since initiating a dividend in 2015, the company has increased its quarterly payout annually.

“We are pleased to increase our dividend again for the eleventh consecutive year. The increase reflects the strength of our balance sheet, consistent cash generation and positive long-term outlook. We remain committed to balanced capital allocation while driving the Enpro 3.0 growth strategy,” said Eric Vaillancourt, President and Chief Executive Officer.

The dividend is payable on March 18, 2026, to shareholders of record as of the close of business on March 4, 2026.

About Enpro

Enpro is a leading industrial technology company focused on critical applications across many end-markets, including semiconductor, industrial process, commercial vehicle, sustainable power generation, aerospace, food and biopharma, photonics and life sciences. Headquartered in Charlotte, North Carolina, Enpro is listed on the New York Stock Exchange under the symbol “NPO”. For more information, visit the company’s website at https://www.enpro.com.

Contacts

Investor Contacts:
James Gentile

Vice President, Investor Relations

Jenny Yee

Corporate Access Specialist

Phone: 704-731-1527

Email: investor.relations@enpro.com

Enpro Inc.
5605 Carnegie Boulevard

Charlotte, NC 28209

www.enpro.com

Cencora Closes $3.0 Billion Senior Notes Offering




Cencora Closes $3.0 Billion Senior Notes Offering

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 3.950% Senior Notes due February 13, 2029 (the “2029 Notes”), $500 million aggregate principal amount of its 4.250% Senior Notes due November 15, 2030 (the “2030 Notes”), $500 million aggregate principal amount of its 4.600% Senior Notes due February 13, 2033 (the “2033 Notes”), $1.0 billion aggregate principal amount of its 4.900% Senior Notes due February 13, 2036 (the “2036 Notes”) and $500 million aggregate principal amount of its 5.650% Senior Notes due February 13, 2056 (the “2056 Notes” and, together with the 2029 Notes, the 2030 Notes, the 2033 Notes and the 2036 Notes, the “Notes”), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the “SEC”) on November 26, 2024.

Cencora intends to use the net proceeds from the offering to repay amounts outstanding under Cencora’s 364-Day Term Credit Agreement, dated as of January 12, 2026, which was used to fund a portion of Cencora’s acquisition of OneOncology, and, to the extent any proceeds remain, for general corporate purposes.

The joint book-running managers for the offering were Citigroup Global Markets Inc., J.P. Morgan Securities LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC. Cencora filed a final prospectus supplement and an accompanying prospectus with the SEC in connection with the offering of the Notes. Copies of these materials can be made available by contacting: Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, email: prospectus@citi.com or telephone: 1-800-831-9146; J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179, Attention: Investment Grade Syndicate Desk, 3rd Floor, telephone collect at 1-212-834-4533; BofA Securities, Inc., NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255, Attention: Prospectus Department, email: dg.prospectus_requests@bofa.com or telephone: 1-800-294-1322; and Wells Fargo Securities, LLC, 608 2nd Avenue South, Suite 1000, 608 2nd Avenue South, Suite 1000, Minneapolis, Minnesota 55402, Attention: WFS Customer Service, email: wfscustomerservice@wellsfargo.com or telephone: 1-800-645-3751. Electronic copies of the final prospectus supplement and accompanying prospectus are also available on the SEC’s web site at www.sec.gov.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cencora

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 51,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $300 billion in annual revenue.

Cencora’s Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”). Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “sustain,” “synergy,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. A more detailed discussion of the risks and uncertainties that could cause our actual results to differ materially from those indicated is included in the “Risk Factors” and “Management’s Discussion and Analysis” sections in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025 and elsewhere in that report and other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.

Contacts

Bennett S. Murphy

Senior Vice President, Investor Relations and Enterprise Productivity

610-727-3693

bennett.murphy@cencora.com

Zeon Corporation Makes Strategic Investment in Chemify to Accelerate Digital Chemistry Innovation and Drive Development of New Materials Through State-of-the-Art Automated Molecular Design and Synthesis




Zeon Corporation Makes Strategic Investment in Chemify to Accelerate Digital Chemistry Innovation and Drive Development of New Materials Through State-of-the-Art Automated Molecular Design and Synthesis

Partnership supports Chemify’s application of its Chemputation technology to design and make novel compounds and materials for Zeon

TOKYO & GLASGOW, Scotland & SAN JOSE, Calif.–(BUSINESS WIRE)–#Chemifarm–Zeon Corporation (Zeon; head office: Chiyoda-ku, Tokyo; President and CEO: Tetsuya Toyoshima), through its venture capital arm Zeon Ventures Inc. (California, U.S.A.; representative: Kazuhiro Takahashi), has strategically invested in and partnered with Chemify, Ltd. (Chemify), a U.K. growth-stage company and pioneer in digital chemistry for accelerating the design, discovery, and synthesis of novel molecules for medicines and advanced materials.

Chemify is at the forefront of digitizing and automating the entire chemical discovery and synthesis process. Chemify’s Chemputation technology translates target molecules into proven chemical code that runs directly on the company’s robotic systems, enabling fully automated Design–Make–Test–Analyze cycles. By automating the end-to-end cycle from molecular design to synthesis and analysis, Chemify can access novel chemical space and potentially achieve a 10-fold reduction in the time required from initial conception to compound synthesis. Last year, Chemify opened its first Chemifarm, a fully automated chemistry facility in Glasgow, Scotland, one of the world’s most advanced laboratories for molecular design and synthesis. This facility enables automated synthesis and rapid iteration for the discovery of novel small molecules moving from code to compound faster than ever, fueling innovations in advanced materials and beyond.

The development of novel, makeable molecules is essential to helping address global challenges in human health, energy conservation, and environmental sustainability. Zeon Corporation has been an early adopter of digital transformation in chemical research, seeking to redefine the future of R&D since the field’s infancy. Through this investment and partnership, we aim to leverage Chemify’s cutting-edge technology to further accelerate our digital chemistry initiatives and drive the creation of new materials and compounds that can provide meaningful solutions to society’s most pressing challenges.

In the STAGE30 medium-term management plan, Zeon Corporation aims to raise the sales ratio of four growth areas (Mobility, Healthcare and Life Science, Telecommunications and Green Transformation) to 48% of total sales by fiscal 2028. Going forward, Zeon will continue to contribute to a ‘sustainable planet’ and ‘safe and comfortable society’ by investing in and supporting innovative companies and developing new materials that can transform various fields and industries.

Outline of Chemify

Company Name: Chemify, Ltd.

Business: Molecular design, discovery and automated synthesis

Representative: Lee Cronin

Address: 11 Chapel Lane, Glasgow G11 6 EW

URL: https://www.chemify.io/

Outline of Zeon Ventures

Company Name: Zeon Ventures, Inc.

Business: Investment in startup companies and other activities

Representative: Kazuhiro Takahashi

Address: 25 Metro Drive, Suite 238, San Jose, California 95110

Investment Scale: US$ 50 million

URL: https://www.zeon.ventures/

Contacts

For Chemify
Tim Ingersoll

Linnden Communications

Tim@linndencom.com

For Zeon Corporation
Department of Corporate Communications

Corporate Sustainability Division

Contact Form